Skip to content
OpenCapital
Get started

Castle Biosciences CSTL Business Segments — Equity Securities, FV-NI, Gain (Loss)

Similar metrics at other companies

Kroger logo
KRReportable Segment Aggregation Before Other Operating — Equity Securities Fv Ni Gain Loss
-$14M+26.3%
Booking Holdings Inc. logo
BKNGReportable Segment — Net gains (losses) on equity securities (3)
-$107M-3,667%
Freshpet logo
FRPTReportable Segment — Gain on equity investment
$62.01M—
WEBTOON Entertainment Inc. logo
WBTNReportable Segment — Gain (loss) on equity method investments, net
-$446K+21.6%
Cronos Group logo
CRONReportable Segment — Gain (loss) on revaluation of financial instruments
-$2.48M-5,169%
Roivant Sciences logo
ROIVReportable Segment — Gain (Loss) on Investments
$21.59M+201%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.

The official record: Castle Biosciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's business segments — equity securities, fv-ni, gain (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's business segments — equity securities, FV-NI, gain (loss)?
Castle Biosciences (CSTL) reported business segments — equity securities, FV-NI, gain (loss) of $366.5K in Q4 2025.
How has Castle Biosciences's business segments — equity securities, FV-NI, gain (loss) changed year-over-year?
Castle Biosciences's business segments — equity securities, FV-NI, gain (loss) increased by 164.1% year-over-year, from $138.75K to $366.5K.
What does business segments — equity securities, FV-NI, gain (loss) mean?
This measures the total gains or losses recognized in the income statement resulting from changes in the fair value of equity securities held by the segment. It highlights the financial performance of the segment's investment portfolio relative to market conditions.